Physician profile
Heather F Mccown
NPI 1932149549
$19,582.43
in general payments reported to CMS, 2019-2025
38 companies · $3,299 in 2025
The $3,299 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,948 · 2020: $1,860 · 2021: $2,210 · 2022: $2,689 · 2023: $3,239 · 2024: $3,337 · 2025: $3,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,731 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,730.72 |
| Education | $144.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,760.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,568.17 | 2019-2025 | |
| Janssen Biotech, INC. | $1,481.62 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $1,470.16 | 2019-2025 | Ilumya, Winlevi |
| Regeneron Healthcare Solutions, INC. | $1,253.87 | 2019-2025 | Dupixent, Libtayo |
| Pfizer INC. | $1,185.51 | 2019-2025 | |
| Amgen INC. | $1,011.42 | 2019-2025 | Otezla, Otezla |
| Lilly USA, LLC | $871.06 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $862.89 | 2019-2025 | Jublia, Cabtreo, Siliq |
| Leo Pharma INC. | $771.72 | 2019-2025 | Adbry, Anzupgo, Spevigo |
| Galderma Laboratories, L.P. | $744.12 | 2019-2025 | Nemluvio, Dysport |
| Ucb, INC. | $710.29 | 2019-2025 | Bimzelx, Cimzia |
| Almirall LLC | $640.84 | 2019-2025 | Klisyri, Seysara |
| Merz North America, INC. | $596.95 | 2019-2023 | |
| Incyte Corporation | $548.22 | 2021-2025 | Opzelura |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $541.69 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $369.38 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $340.84 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.53 | 2022-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $268.45 | 2020-2021 | |
| Allergan, INC. | $244.95 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $212.74 | 2022-2025 | Sotyktu |
| Mayne Pharma Commercial LLC | $163.60 | 2019-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $116.93 | 2019-2023 | Valchlor |
| Organon LLC | $116.68 | 2025 | Vtama |
| Celgene Corporation | $105.07 | 2019 | |
| Genentech USA, INC. | $72.75 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $49.14 | 2019 | |
| Epi Health, LLC | $44.84 | 2021-2022 | |
| Aclaris Therapeutics, INC. | $38.33 | 2019 | |
| Journey Medical Corporation | $34.19 | 2022 | |
| Biofrontera INC. | $25.24 | 2022-2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Kerecis Limited | $17.81 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Sensus Healthcare, INC. | $15.81 | 2020 | |
| Smith+Nephew, INC. | $15.15 | 2024 | Grafix Pl |
| Organogenesis INC. | $14.00 | 2023 | Puraply |
| Mylan Pharmaceuticals INC. | $12.22 | 2019 | |
| Taro Pharmaceuticals USA, INC. | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Mccown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.